A series of high specific activity accelerator-produced radionuclides in no-carrier-added (NCA) form, for uses in metabolic radiotherapy and for PET, has been investigated and produced at JRC-Ispra Cyclotron Lab. Here, the authors present the NCA 211At/211gPo (LET = 130 eV.nm-1, t1/2 = 7.214 h), produced by the 209Bi(α,2n) reaction, with internal spike of gamma emitter 210At (e.g., negligible amt. of 210Po as radiotoxic long-lived impurity), for high-LET targeted radiotherapy and immunoradiotherapy. A selective radiochem. sepn., based on liq./liq. extn., of At radionuclides from Bi target and Po impurities has been developed. High resoln. gamma, x- and alpha spectrometric techniques have been adopted for quality controls of different radiochem. fractions.
Alpha cyclotron production studies of the alpha emitter 211At/211gPo for high-LET metabolic radiotherapy / S. Morzenti, M.L. Bonardi, F. Groppi, C. Zona, L. Canella, E. Menapace, Z.B. Alfassi, K. Abbas, U. Holzwarth - In: Astroparticle, particle and space physics, detectors and medical physics applications : proceedings of the 9th conference, Villa Olmo, Como, Italy, 17-21 October 2005 / [a cura di] M. Barone. - Singapore : World Scientific, 2006. - ISBN 9812567984. - pp. 742-746 (( Intervento presentato al 9. convegno Astroparticle, Particle and Space Physics, Detectors and Medical Physics Applications tenutosi a Como nel 2005.
Alpha cyclotron production studies of the alpha emitter 211At/211gPo for high-LET metabolic radiotherapy
S. MorzentiPrimo
;M.L. BonardiSecondo
;F. Groppi;C. Zona;
2006
Abstract
A series of high specific activity accelerator-produced radionuclides in no-carrier-added (NCA) form, for uses in metabolic radiotherapy and for PET, has been investigated and produced at JRC-Ispra Cyclotron Lab. Here, the authors present the NCA 211At/211gPo (LET = 130 eV.nm-1, t1/2 = 7.214 h), produced by the 209Bi(α,2n) reaction, with internal spike of gamma emitter 210At (e.g., negligible amt. of 210Po as radiotoxic long-lived impurity), for high-LET targeted radiotherapy and immunoradiotherapy. A selective radiochem. sepn., based on liq./liq. extn., of At radionuclides from Bi target and Po impurities has been developed. High resoln. gamma, x- and alpha spectrometric techniques have been adopted for quality controls of different radiochem. fractions.
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
